◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW HIGH

THN102

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Program was discontinued by Theranexus in 2022 — no commercial product exists. Even if it returned, narcolepsy Phase 2 missed primary endpoint, modafinil monotherapy already covers Dylan's wake-promoting use case, and adding a class IC antiarrhythmic to a healthy 20yo with no cardiac monitoring infrastructure adds risk without clear consumer benefit. Verdict would shift to WATCH-LIST only if (a) program revives under licensing partner with positive Phase 3, or (b) Dylan develops residual modafinil non-response after 6+ months of optimization.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Modafinil monotherapy (already PRIMARY-PICK in V5 plan) covers the wake-promoting and cognitive-output use case. The marginal benefit demonstrated for THN102 was in 40-hour total sleep deprivation (extreme condition Dylan does not face) and in Parkinson's EDS (not Dylan's condition). Adding a Vaughan-Williams class IC antiarrhythmic to a 20yo with no cardiac monitoring, no baseline ECG, no CYP2D6 phenotype, and high-cardio MMA training is poor risk/reward. Even if the program revives, modafinil alone remains the cleaner default.

  • 30-50, executive maintenance
    SKIP-FOR-NOW

    Same reasoning. Modafinil monotherapy + caffeine + L-theanine handles this archetype cleanly; THN102 adds cardiac complexity for marginal cognitive benefit unsupported by replication.

  • 50+, mild cognitive decline
    SKIP-FOR-NOW

    Cardiac contraindications more common in this age group (HTN, structural heart disease, electrolyte issues). Flecainide is exactly the wrong drug to add casually to this population. Donepezil or modafinil monotherapy preferred.

  • Anxiety-prone
    SKIP

    Flecainide's negative inotropy + palpitation risk could amplify cardiac-anxiety presentations. Wrong tool.

  • High athletic load, tested status
    SKIP

    Modafinil banned in-competition (S6); flecainide not specifically banned but is an Rx cardiac drug requiring TUE. Wrong tool.

  • Sleep-disordered (narcolepsy specifically)
    WATCH-LIST

    The mechanism is interesting and one Phase 2a (Parkinson's) supports the Cx30 hypothesis at the right dose. If a partner revives the program and Phase 3 narcolepsy data emerges positive, this could become a real option for narcolepsy patients with residual sleepiness on modafinil monotherapy. Not relevant to Dylan (no narcolepsy diagnosis).

  • Recovery-focused (post-injury, post-illness)
    SKIP

    No injury/recovery indication explored. Modafinil alone or solriamfetol are better-evidenced choices for post-concussion fatigue or post-COVID brain fog.

  • Strength/anabolic-focused
    SKIP

    No anabolic effect; cardiac risk profile actively unhelpful with high-volume training.

▸ Subjective experience (deep)

Important caveat: THN102 has only been studied in clinical trial settings. There is no consumer-use subjective database equivalent to what exists for modafinil.

From Sauvet 2019 healthy-volunteer trial:

  • Vigilance improvements were more sustained (6 vs 3 timepoints across 40 hr sleep deprivation) — the objective basis for "smoother and longer" framing.
  • Side-effect rates including somnolence, fatigue, headache, and nausea were numerically lower than modafinil alone — possibly an indirect signal of better tolerability, possibly small-n noise.

From Parkinson's Phase 2a:

  • ESS reduction at the 200/2 dose was clinically meaningful in patients with substantial baseline EDS.
  • Patients did not report adverse effects on motor or other PD symptoms.

What we CAN'T say honestly:

  • No head-to-head subjective comparison vs modafinil monotherapy in healthy users with daily-use cognitive enhancement context.
  • The "smoother + longer wakefulness" framing is plausible based on PVT data over time, but is not the same as a user-reported preference signal that exists for modafinil vs armodafinil. Treat the marketing-style framing of "smoother + longer than modafinil alone" with skepticism — the underlying data is one 20-person trial in extreme sleep-deprivation conditions.
▸ Tolerance + cycling deep dive
  • Unknown. Long-term THN102 tolerance was never characterized — Phase 2 studies were 2-12 weeks max in crossover format.
  • Modafinil tolerance pattern (see modafinil.md) — minimal in clinical narcolepsy data, anecdotally variable.
  • Flecainide chronic use (cardiology context) — does not show tachyphylaxis to its antiarrhythmic effect; chronic use over years is well characterized in stable patients. Tolerance to Cx30 effects is unknown.
  • No recommended cycle because no long-term consumer use data exists.
▸ Stacking deep dive

Synergistic with

  • Modafinil (tautologically — flecainide is the modafinil-amplifier).
  • L-theanine — would smooth modafinil-component anxiety, no flecainide interaction.
  • Magnesium — may reduce flecainide proarrhythmic risk via membrane stabilization, plausibly synergistic for safety.
  • Citicoline — neutral, supports cholinergic side of cognition.

Avoid stacking with

  • Other CYP2D6 inhibitors: SSRIs (especially paroxetine, fluoxetine), bupropion, terbinafine — raise flecainide levels.
  • Beta-blockers: Additive negative inotropy.
  • Other antiarrhythmics: Amiodarone, sotalol, quinidine — additive proarrhythmia.
  • High-dose stimulants: Amphetamines, high-dose caffeine — catecholamine surge increases proarrhythmia risk in flecainide-treated patients.
  • Loop or thiazide diuretics without K+/Mg2+ monitoring — electrolyte shifts unmask flecainide arrhythmia.
  • Ketamine, MDMA, cocaine — sodium channel + cardiac stress overlap is dangerous.

Neutral / safe co-administration

  • All Dylan's V4 supplements appear neutral on paper, but the operative point is that no daily-use safety dataset exists for THN102 at all.
▸ Drug interactions deep dive

Combined profile inherits both modafinil's and flecainide's interaction profiles:

  • Modafinil: CYP3A4 induction (reduces hormonal contraceptive efficacy, opioid analgesia, cyclosporine, midazolam levels); CYP2C19 inhibition (raises phenytoin, diazepam, omeprazole, propranolol levels).
  • Flecainide: CYP2D6 substrate (highly sensitive to CYP2D6 inhibitors — paroxetine, fluoxetine, bupropion, quinidine, terbinafine, ritonavir all elevate levels significantly).
  • Modafinil + flecainide cross-interaction: Modafinil's mild CYP2C19 inhibition can indirectly increase flecainide exposure in CYP2D6 poor metabolizers (who lean on 2C19 as backup). This is exactly the population where flecainide can shift from sub-antiarrhythmic to arrhythmogenic doses.
▸ Pharmacogenomics

The clinically dominant variable is CYP2D6 status:

  • ~7-10% of Caucasians are CYP2D6 poor metabolizers (PM, Dylan's ancestry).
  • ~1-3% are ultra-rapid metabolizers (UM).
  • PMs have ~40-50% higher flecainide exposure on standard doses.
  • UMs have lower exposure → lower efficacy at standard doses.
  • THN102's narrow therapeutic margin (1-3 mg flecainide effective; ≥10 mg approaches cardiac risk territory) means CYP2D6 status would be required pre-screening for any safe consumer use. Dylan's status: unknown until 23andMe results June 2026.

CYP2C19 (modafinil): Standard modafinil pharmacogenomics apply (see modafinil.md). PMs ~20-30% higher modafinil exposure on standard doses.

Other: No HLA, ADRA, or sodium-channel polymorphism associations specifically validated for THN102.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Theranexus (now THX Pharma) — original developer N/A N/A N/A Program discontinued 2022. Company pivoted to Batten disease (Batten-1 / miglustat). No commercial THN102 product exists or is under active development.
Licensee / partner None known N/A N/A Theranexus failed to find an industrial partner in 2020-2021; equity financing line with Iris Capital interrupted in Jan 2022. As of Nov 2025 (THX Pharma €7.8M raise), pipeline is exclusively Batten-1.
Generic Rx flecainide + Indian pharmacy modafinil (DIY) Tambocor (flecainide), Modalert (modafinil) Modafinil ~$0.80/200mg pill; flecainide 50mg tablet ~$0.50/each US Rx Not recommended — see below DIY combination requires (1) cardiology Rx for flecainide, which no honest cardiologist will write absent an arrhythmia diagnosis; (2) sub-antiarrhythmic dosing requires pill-cutting a 50mg flecainide tablet to ~1/25 size = impractical and highly variable; (3) baseline + serial ECG monitoring; (4) CYP2D6 phenotyping. Not commercially or practically achievable as a consumer product.
Compounding pharmacy Various US compounding pharmacies Variable, would require Rx Theoretically possible, practically zero Even if a willing prescriber existed, a compounding pharmacy would need a clinical justification for the specific combination — there is none for healthy adults.

Bottom line: THN102 is not available on any market or gray market. Even DIY assembly is impractical and unsafe absent cardiac monitoring infrastructure.

▸ Biomarkers to track (deep)

Not applicable — verdict is SKIP. If hypothetically pursued (academic only):

  • Baseline: 12-lead ECG, BP, HR, electrolytes (K, Mg), liver panel, CYP2D6 phenotype, modafinil-relevant baselines (sleep VAS, anxiety, skin photo for SJS watch).
  • Weeks 1-4: ECG (PR, QRS, QT trends), HR, BP, daily symptom log (palpitations, syncope, dyspnea = stop immediately).
  • Long-term: ECG every 6 months, electrolytes any time intercurrent illness or diuretic use.
▸ Controversies / open debates Live debate

1. Did THN102 actually beat modafinil monotherapy?

  • Sleep-deprivation Phase 1/2 (n=20 healthy men): Yes — primary endpoint hit, secondary endpoints positive, dose-response curiously flat across 1-9 mg flecainide.
  • Narcolepsy Phase 2 (n=48): No — primary endpoint not met. Theranexus argued modafinil-non-responder enrichment of the patient population was the issue.
  • Parkinson's Phase 2a (n=75): Hit primary vs placebo — not vs modafinil monotherapy. The Parkinson's paper does not establish THN102 superiority over modafinil 200 mg alone in this population.
  • Honest summary: Mixed evidence for THN102 superiority over modafinil in human trials. Strongest signal is in extreme sleep deprivation (one trial, n=20, military funded). Mechanism is real but clinical translation has been inconsistent.

2. Is the mechanism real?

  • Preclinical mouse data is robust — Cx30 modulation by flecainide, modafinil's effect on Cx30 expression, synergistic wake effects.
  • The Sauvet 2019 sleep deprivation human data suggests the mechanism transfers — at least in one context.
  • Open question: Does Cx30 modulation matter for healthy daily-use cognitive enhancement (where modafinil works fine alone) vs only for pathological sleep states where modafinil is partially overcome? The Phase 2 narcolepsy failure suggests possibly the latter.

3. Why did Theranexus drop the program?

  • Per company communications: failed to secure an industrial partner after positive Parkinson's data; pipeline rationalization to focus on rare neurological disease (Batten disease) for direct commercial launch capability.
  • Per industry observers: narcolepsy Phase 2 failure made the broad-indication strategy harder to finance; capital-intensity of a Phase 3 in a competitive market (modafinil + armodafinil generic; pitolisant; solriamfetol all approved) made a Phase 3 a tough capital ask without a partner.
  • Implication: Discontinuation does not necessarily mean "drug doesn't work." It means the commercial case for a Phase 3 in CNS broad indications wasn't compelling enough to find a partner. Could revive under different ownership; no signs of this as of May 2026.

4. Is sub-antiarrhythmic flecainide actually safe in healthy people?

  • THN102 trial data (cumulative n=143 across three trials): No cardiac signal observed at the doses tested, including ECG monitoring.
  • Clinical population: Generally older patients (Parkinson's), narcolepsy adults, healthy military-age men. None had structural heart disease.
  • Open question: What about subclinical structural disease in self-selecting consumers? Untested. The CAST trial lesson is that flecainide is dangerous specifically in structural heart disease, and this is not always known pre-dose without imaging. The risk profile in unselected consumers is not characterized.

5. Does flecainide really not affect modafinil plasma levels?

  • Confirmed in PK studies — flecainide does not alter modafinil pharmacokinetics. The mechanism is genuinely pharmacodynamic via Cx30, not pharmacokinetic.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW / HIGH CONFIDENCE. Program discontinued by Theranexus 2022; no commercial product; modafinil monotherapy already PRIMARY-PICK for Dylan's use case; class IC antiarrhythmic adds cardiac complexity without consumer benefit at age 20. Confidence is HIGH because the situation is dispositive on commercial availability alone — even if mechanism is interesting, there is no path to obtain a properly formulated product. WATCH-LIST flag on the off-chance a partner revives the program with Phase 3 narcolepsy data.
▸ Open questions / gaps Open
  1. Will the program revive? No public signals as of May 2026. THX Pharma is fully focused on Batten-1 (miglustat) per Nov 2025 €7.8M raise. Worth a single-query check at next refresh (May 2027) but expect "still discontinued."
  2. Does sub-antiarrhythmic flecainide modulate Cx30 in chronic daily-use without target adaptation? Long-term Cx30 saturation tachyphylaxis is unknown. Mouse data suggests the effect persists but no >12 week human data exists.
  3. Independent replication of Sauvet 2019 sleep deprivation data? None as of May 2026. The original trial was DGA-funded and Theranexus-affiliated; an independent group has not replicated.
  4. CYP2D6 PM safety margin at 1-2 mg flecainide? Unstudied. The narrow effective dose range + ~50% higher exposure in PMs creates a theoretical risk that has not been characterized in any THN102 trial because no published trial stratified by CYP2D6 phenotype.
  5. Why did the higher flecainide dose (200/18) fail in Parkinson's while the lower (200/2) succeeded? Possible explanations: target-saturation inverted-U dose-response on Cx30; off-target effects emerging at higher dose; sample noise. Unresolved and worth following if the program ever revives.
▸ Sources (full, with our context)
Back to compact view